With uncertainty regarding the benefits and toxicity concerns with multiple myeloma candidate selinexor from Karyopharm Therapeutics Inc. (NASDAQ:KPTI), FDA's Oncologic Drugs Advisory Committee voted 8-5 that FDA should delay a decision on the product's approval until data from the Phase III BOSTON trial are available.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,